About Revolution Medicines
Revolution Medicines (NASDAQ:RVMD) focuses on developing new drug candidates to outsmart cancer. Their operations span from early discovery to advanced clinical trials, aiming to tackle malignancies by disrupting the core pathways that cancer cells depend on for growth and survival. The company's projects primarily revolve around precision oncology, with an emphasis on frontier cancer targets that have evaded traditional therapeutic approaches. These include efforts to inhibit elusive tumors driven by RAS or mTOR pathway mutations. Revolution Medicines is deeply invested in transforming cancer treatment paradigms by delivering innovative, targeted therapies that address the complex challenges of refractory cancers. Their objective is not just to extend life but to improve the quality of life for patients battling cancer.
Snapshot
Operations
Produtos e/ou serviços de Revolution Medicines
- RMC-4630, a potent SHP2 inhibitor being developed as a novel treatment for cancers driven by MAPK pathway mutations.
- RMC-5552, targeting mTORC1/4EBP1, developed for treating tumors resistant to current mTOR inhibitors.
- RMC-6236, a RAS(ON) inhibitor aimed at directly targeting a range of RAS mutations in various cancers.
- RMC-6291, another RAS(ON) inhibitor, specifically targeting KRAS G12C mutant cancers, expanding the therapeutic options.
- RMC-9805, focused on KRAS G12D mutations, providing a targeted approach for a challenging oncogenic driver.
- FOP program dedicated to developing inhibitors for the FGFR1 signaling pathway, offering potential treatments for skeletal disorders.
equipe executiva do Revolution Medicines
- Dr. Mark A. Goldsmith M.D., Ph.D.CEO, President & Chairman
- Mr. Jack AndersChief Financial Officer
- Ms. Margaret A. Horn J.D.Chief Operating Officer
- Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.President of Research & Development
- Ms. Xiaolin WangExecutive Vice President of Development
- Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory Board
- Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory Board
- Mr. Walter Reiher Ph.D.Chief Information Officer
- Ms. Jan Smith Ph.D.Chief Scientific Officer